MAP2K1 and acute myeloid leukemia: In contrast to AC-4-130 and PTC596, the MEK1 inhibitor trametinib and the FLT3 inhibitor PKC412 (midostaurin) were less effective in the AML cells in the presence of HS-5 stroma.